-
Loading metrics
Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country
- Thang Xuan Do,
- Ha Thi Nguyen,
- Phuong Thi Lan Nguyen,
- Mai Thi Tuyet Kieu,
- Tuan Viet Duong,
- Van Nu Hanh Pham
x
- Published: April 3, 2026
- https://doi.org/10.1371/journal.pone.0345212